Unlearn.AI Valuation, Funding & Investors
Unlearn.AI is valued at $265M as of March 2023.
Last Unlearn.AI valuation
$265M
Undisclosed stage · Mar 2023
Last Unlearn.AI funding round
$50M
Series C · Feb 2024
Cumulative funding Unlearn.AI raised
$135M
across 7 funding rounds
Key investors in Unlearn.AI
DCVC
DCVC Bio
8VC
Radical Ventures
Necessary Ventures
Alumni Ventures
About Unlearn.AI
Unlearn.AI is a clinical trial platform generating digital twins of patients using machine learning models trained on historical data. Its TwinRCT design accelerates biopharma studies by reducing required participants while maintaining statistical power for endpoints. Headquartered in San Francisco, the company partners with Pfizer and Roche on trials for Alzheimer's and oncology indications.
Founded
2017
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Services, Subscription
Valuation
$265M (Mar 2023)
Unlearn.AI Valuation
Unlearn.AI is currently valued at $265M, based on its undisclosed-stage round in March 2023.
The $15M round was led by Radical Ventures and Wittington Ventures.
Unlearn.AI valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2023 | Undisclosed stage | $265M |
Unlearn.AI Funding History
Unlearn.AI has raised a total of $135M across 7 funding rounds.
Unlearn.AI's first fundraising round was a $700K pre-seed round in August 2017. The most recent completed round was a $50M Series C in February 2024.
Unlearn.AI funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Feb 2024 | Series C | Altimeter Capital (lead); DCVC Bio; 8VC; Wittington Ventures; Radical Ventures; DCVC; Mubadala Capital; EPIC Ventures; Insight Partners; Necessary Ventures | $50M | - | Unlearn.AI is a San Francisco-based AI company founded in 2017 that develops digital twins of clinical trial participants to enable smaller, faster, and more ethical studies, addressing challenges like lengthy timelines, slow enrollment, and placebo hesitancy in clinical trials. The platform uses AI to optimize clinical research, reduce trial and error in medicine, and accelerate the delivery of therapeutics by creating digital replicas that support pharmaceutical partners. In February 2024, Unlearn.AI raised $50 million in a Series C funding round led by Altimeter Capital, with participation from returning investors including Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital, as well as existing backers like Insight Partners, 8VC, DCVC, and DCVC Bio. This round brings the company's total funding to over $130 million across prior rounds: Seed ($4.2M in March 2019 led by DCVC Bio), Series A ($12M in April 2020 led by 8VC), and a prior Series B. The funds will be deployed to invest in personnel, data capabilities, engineering, long-term R&D, computing power, and expansion into additional therapeutic areas to build awareness and demonstrate value. Investors highlight Unlearn's innovative AI application in transforming clinical trials, streamlining research, reducing participant needs, and improving outcomes for the pharmaceutical industry. No public disclosure of post-money valuation, revenue, ARR, EBITDA, or valuation multiples was found in announcements. The company continues to focus on proving its technology's reliability amid industry skepticism and regulatory constraints, with potential for future fundraising or partnerships. |
| Mar 2023 | Undisclosed stage | Radical Ventures (lead); Wittington Ventures (lead) | $15M | $265M | Unlearn.AI develops AI-powered digital twin technology to accelerate clinical trials by creating patient replicas, enabling smaller and faster studies while reducing placebo use and addressing challenges like slow enrollment. The company secured $15 million in a March 2023 venture round led by Radical Ventures and Wittington Ventures, valuing it at $265 million post-money. This funding followed regulatory approval from the European Medicines Agency for its AI approach and multi-million dollar partnerships with pharmaceutical firms including Merck. The investment supports expansion of partnerships and acceleration of regulatory approvals across therapeutic areas. Unlearn.AI, founded in 2017 and based in San Francisco, applies generative AI to simulate health outcomes for trial participants, populating control arms with digital twins to lower costs for drug developers. Mira Murati from OpenAI joined the board around this time. Previous rounds include a $50 million Series B in April 2022 led by Insight Partners. Subsequent funding comprised a $50 million Series C in early 2024 led by Altimeter Capital, bringing total capital raised to over $130 million and advancing AI to eliminate trial-and-error in medicine. |
| Apr 2022 | Series B | Insight Partners (lead); DCVC Bio; 8VC; Radical Ventures; DCVC; Mubadala; Parkway Venture Capital | $50M | - | Unlearn.AI develops machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies using its TwinRCTs platform, which leverages historical data and AI to simulate trial outcomes while aligning with regulatory standards. The Series B funding round on April 19, 2022, raised $50 million led by Insight Partners, with participation from Radical Ventures and existing investors including 8VC, DCVC, DCVC Bio, and Mubadala Capital Ventures. The funds aimed to advance product development, expand work with global biopharmaceutical companies, and engage with regulatory authorities like the FDA and EMA, which have supported the technology's use in phase 2 and 3 trials. CEO Charles Fisher highlighted the financing as validation of Unlearn's growing footprint in clinical trials amid industry skepticism toward new technologies. Prior to this round, Unlearn had raised approximately $19.85 million across pre-seed, seed, and Series A rounds, bringing the total to $69.85 million post-Series B, with plans to double its 40-person headcount and enter new therapeutic areas. |
| Nov 2020 | Series A | Alumni Ventures; Eisai Co.; EPIC Ventures | $3M | - | Unlearn.AI develops a machine-learning platform that creates digital twins of patients to generate intelligent control arms for clinical trials, accelerating studies in areas like Alzheimer's disease. The company raised a $3 million Series A extension in November 2020 from Eisai, Epic Ventures, and Alumni Ventures Group, following its $12 million Series A in April 2020 led by 8VC. This funding supported expansion in Alzheimer's and other therapeutic areas, addressing challenges like enrollment delays and high failure rates. Unlearn.AI's technology has shown capacity to increase trial power and mitigate COVID-19 impacts on studies. |
| Apr 2020 | Series A | 8VC (lead); DCVC Bio; Castor Ventures; Alumni Ventures; DCVC; Mubadala; Necessary Ventures | $12M | - | Unlearn.AI develops a machine-learning platform that creates Digital Twins to populate Intelligent Control Arms in clinical studies, improving trial efficiency by generating virtual patient data from historical datasets. The company closed a $12 million Series A funding round on April 20, 2020, led by 8VC with participation from existing investors DCVC, DCVC Bio, and Mubadala Capital Ventures. 8VC Principal Francisco Gimenez joined the Unlearn.AI board. The financing supports team expansion from about 15 to double that size within a year and advances the Digital Twin technology for broader clinical trial applications. CEO Charles Fisher emphasized progress with regulators and commercial partners running studies with Digital Twins to boost trial success rates. Unlearn.AI prioritizes building a track record for faster trials over immediate revenue, targeting pharmaceutical companies with high-value drugs. Prior to this round, Unlearn.AI had raised approximately $5 million in pre-seed and seed rounds. The Series A brings total funding to $17 million at that point. |
| Mar 2019 | Seed | DCVC Bio (lead); Necessary Ventures | $4M | - | Unlearn.AI raised $4.2 million in a seed round in March 2019 led by DCVC Bio to further develop AI technology and validate the digital twin concept for clinical trials. The company, founded in 2017, uses AI to create digital twins of clinical trial participants, enabling smaller and faster studies by generating synthetic control patient data from historical datasets. Prior to this round, Unlearn.AI completed a pre-seed round of $650K in August 2017 led by DCVC to establish the company and develop initial AI models. |
| Aug 2017 | Pre-seed | DCVC (lead) | $700K | - | - |
Who has invested in Unlearn.AI?
15 investors have backed Unlearn.AI across its funding rounds, including DCVC, DCVC Bio, 8VC, Radical Ventures, Necessary Ventures and Alumni Ventures.
Lead investors include Altimeter Capital, Radical Ventures, Wittington Ventures, Insight Partners, 8VC and 2 other investors.
Unlearn.AI Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 4 | Lead | Mar 2019 | |
| United States | 4 | Lead | Aug 2017 | |
| San Francisco, CA | 3 | Lead | Apr 2020 | |
 Toronto | 3 | Lead | Apr 2022 | |
| San Francisco, CA | 3 | Participant | Mar 2019 | |
| Toronto | 2 | Lead | Mar 2023 | |
| United States | 2 | Participant | Apr 2020 | |
| Salt Lake City, UT | 2 | Participant | Nov 2020 | |
 Abu Dhabi | 2 | Participant | Apr 2020 | |
| New York City, NY | 2 | Lead | Apr 2022 | |
| Boston, MA | 1 | Participant | Apr 2020 | |
| San Francisco, CA | 1 | Lead | Feb 2024 | |
 Tokyo | 1 | Participant | Nov 2020 | |
This data is available for Pro users. Sign up to see all 15 Unlearn.AI investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialUnlearn.AI Competitors
Unlearn.AI competitors include listed companies like Coveo Solutions and Medipost, and private ones like Fish Audio, K25.ai, Polsia and Babel Technology.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| San Francisco, CA | Private | $21M | - | $260M | 12.4x | |
| Canada | Publicly listed | $148M | ($25M) | $276M | 1.2x | |
 Singapore | Private | - | - | $250M | - | |
| Los Angeles, CA | Private | $10M | - | $250M | 25.0x | |
 Beijing | Private | $230M | $29M | $300M | 1.3x | |
 South Korea | Publicly listed | $54M | ($59M) | $255M | 4.7x |
Unlearn.AI Public Comps
Unlearn.AI is still privately-owned, but its public comps include Dishman Carbogen Amics, Lyell Immunopharma, Oryzon Genomics, ProQR Therapeutics, Surgical Science, AC Immune, Macrogenics, Tess Holdings Co, Starpharma and Entrada Therapeutics.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $300M | $60M | 1.6x | - | 8.0x | - | |||
| $36K | ($276M) | 2714.8x | 5488.9x | (0.4x) | (0.5x) | |||
| - | ($6M) | - | 34.6x | (39.8x) | (31.0x) | |||
| $18M | ($47M) | 8.2x | 7.9x | (3.2x) | (2.3x) | |||
| $101M | $18M | 1.9x | 1.9x | 11.2x | 9.4x | |||
| $4M | ($85M) | 41.0x | 9.5x | (2.1x) | - | |||
| $150M | ($66M) | 0.8x | 1.0x | (1.9x) | - | |||
| $236M | $37M | 3.1x | 2.2x | 19.8x | - | |||
This data is available for Pro users. Sign up to see all Unlearn.AI competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Unlearn.AI
| When was Unlearn.AI founded? | Unlearn.AI was founded in 2017. |
| Where is Unlearn.AI headquartered? | Unlearn.AI is headquartered in San Francisco, CA, United States. |
| Is Unlearn.AI publicly listed? | No, Unlearn.AI is a private, VC-backed company. |
| What is Unlearn.AI's valuation? | Unlearn.AI was last valued at $265M in its undisclosed-stage round in March 2023. |
| How much funding has Unlearn.AI raised? | Unlearn.AI has raised $135M across 7 funding rounds. |
| What was Unlearn.AI's last funding round? | Unlearn.AI's last funding round was a $50M Series C in February 2024, led by Altimeter Capital. |
| Who are Unlearn.AI's investors? | Unlearn.AI's investors include DCVC Bio, DCVC, 8VC, Radical Ventures, Necessary Ventures, Wittington Ventures, Alumni Ventures, EPIC Ventures, Mubadala, Insight Partners and 5 others. |
| Which companies are comparable to Unlearn.AI? | Companies comparable to Unlearn.AI include Fish Audio, Coveo Solutions, K25.ai, Polsia, Babel Technology and Medipost. |
See companies similar to Unlearn.AI
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.